Andrew Chantry

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

Andrew Chantry, Clive Buckle, John D. Shaughnessy et al. · Journal of Bone and Mineral Research · 2008 · 241 citations · Full text

Medicine, Molecular Medicine, Bone Metabolism +12

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐<i>κ</i>B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

Evangelos Terpos, Deborah J. Heath, Amin Rahemtulla et al. · British Journal of Haematology · 2006 · 221 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

Andrew Chantry, Debby Heath, Aaron W. Mulivor et al. · Journal of Bone and Mineral Research · 2010 · 147 citations · Full text

Medicine, Cancer Biology, Oncology +17